Role of myocardial hypoxia in the remodeling of the embryonic avian cardiac outflow tract.
The embryonic cardiac outflow myocardium originates from a secondary heart-forming field to connect the developing ventricles with the aortic sac. The outflow tract (OFT) subsequently undergoes complex remodeling in the transition of the embryo to a dual circulation. In avians, elimination of OFT cardiomyocytes by apoptosis (stages 25-32) precedes coronary vasculogenesis and is necessary for the shortening of the OFT and the posterior rotation of the aorta. We hypothesized that regional myocardial hypoxia triggers OFT remodeling. We used immunohistochemical detection of the nitroimidazole EF5, administered by intravascular infusion in ovo, as an indicator of relative tissue oxygen concentrations. EF5 binding was increased in the OFT myocardium relative to other myocardium during these stages (25-32) of OFT remodeling. The intensity of EF5 binding paralleled the prevalence of apoptosis in the OFT myocardium, which are first detected at stage 25, maximal at stage 30, and diminished by stage 32. Evidence of coincident hypoxia-dependent responses included the expression of the vascular endothelial growth factor (VEGF) receptor 2 by the OFT myocardium, the predominant expression of VEGF122 (diffusible) isoform in the OFT, and the recruitment of QH1-positive pro-endothelial cells to the OFT and vasculogenesis. Exposure of embryos to hyperoxia (95% O(2)/5% CO(2)) during this developmental window reduced the prevalence of cardiomyocyte apoptosis and attenuated the shortening and rotation of the OFT, resulting in double-outlet right ventricle morphology, similar to that observed when apoptosis is directly inhibited. These results suggest that regional myocardial hypoxia triggers cardiomyocyte apoptosis and remodeling of the OFT in the transition to a dual circulation, and that VEGF autocrine/paracrine signaling may regulate these processes.
Sugishita
Yasuyuki
Y
Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Watanabe
Michiko
M
Fisher
Steven A
SA
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D002642:Chick Embryo; D017931:DNA Primers; D017341:Etanidazole / Q000031:analogs & derivatives*; D015870:Gene Expression; D006321:Heart / Q000196:embryology*; D006845:Hydrocarbons, Fluorinated; D018496:Hyperoxia / Q000196:embryology; D000860:Hypoxia / Q000196:embryology*; D007150:Immunohistochemistry; D007202:Indicators and Reagents; D009024:Morphogenesis; D009206:Myocardium / Q000166:cytology*; D011784:Quail; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D005466:Fluorocarbons
D017931:DNA Primers; D017341:Etanidazole; D006845:Hydrocarbons, Fluorinated; D007202:Indicators and Reagents; D042461:Vascular Endothelial Growth Factor A; C096011:2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; D005466:Fluorocarbons